Article
Comparison of Creatinine and Cystatin C to Estimate Renal Function in Geriatric and Frail Patients

Erik Dahlén 1,* and Linda Björkhem-Bergman 2

1 Jakobsberg Geriatric Clinic, Jakobsberg’s Hospital, Järfalla, 177 31 Stockholm, Sweden
2 Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Blickagången 16, Neo Floor 7, Huddinge, 141 83 Stockholm, Sweden; linda.bjorkhem-bergman@ki.se
* Correspondence: erik.dahlen@regionstockholm.se

Abstract: The aim of this study was to compare estimated glomerular filtration rate (eGFR) with creatinine (eGFRcrea) and cystatin C (eGFRcys) in geriatric and frail patients. A retrospective, cross-sectional study was performed at a geriatric clinic in Stockholm (n = 95). The revised Lund–Malmö equation was used to calculate eGFRcrea and the Caucasian-Asian-Pediatric-Adult (CAPA) equation was used for eGFRcys. The absolute mean percentage difference between eGFRcrea and eGFRcys was used as a surrogate measure for accuracy in eGFR. Other outcome measures were consistency expressed in Lin’s concordance correlation coefficient and the proportion of consistent staging of renal failure. Subgroup analyses were performed with regard to frailty (according toClinical Frailty Scale) and age. eGFRcys estimated lower GFR than eGFRcrea across the entire study population as well as in all subgroups (p < 0.05). Difference between the estimates increased with increasing frailty ($r^2 = 0.15, p < 0.01$), but was not significantly affected by age ($r^2 = 0.004, p = 0.55$). In conclusion, eGFRcys was significantly lower compared to eGFRcrea in geriatric and frail patients. Moreover, frailty had greater impact than age on the accuracy of eGFR. However, this study cannot determine if any of the estimates are preferable over the other in this patient group.

Keywords: creatinine; cystatin C; frail elderly; geriatrics; glomerular filtration rate; renal insufficiency

1. Introduction

Knowledge of patients’ renal function is of paramount importance in patient safety, especially for assessing renal ability to eliminate drugs. Kidney function is described by glomerular filtration rate (GFR), i.e., the volume of fluid filtered out of plasma through glomeruli per minute. Normal GFR is 100–130 mL/min [1]. From the age of 40–50 years, there is a gradual decline in renal function as part of normal ageing [1]. By the age of 80, GFR is expected to have decreased by 50% [2]. Frail elderly people are a vulnerable group due to polypharmacy and are at increased risk of adverse drug reactions [3]. In Sweden, approximately 10% of emergency admissions of elderly people are due to adverse drug reactions, 60% of which are possibly avoidable [4]. Frailty is a consequence of biological ageing, but not all older people are frail [5].

GFR can be measured (mGFR) by administering an exogenous marker intravenously, e.g., iohexol, and calculating the elimination rate of the substance by a follow-up urine or blood sample. However, this is time consuming and resource intensive and is only used when a precise estimation of renal function is necessary, e.g., before chemotherapy or kidney donation [1]. In clinical practice, endogenous markers are measured instead, using mathematical equations to give an estimated GFR (eGFR) without the need to measure elimination rate. eGFR can be calculated in absolute numbers or relative to a standardized body surface area of 1.73 m². Relative eGFR is used for assessing degree of renal impairment (Table 1) and absolute eGFR is used for dosage of drugs [1].
Table 1. Stages of chronic renal failure according to Kidney Disease Outcomes Quality Initiative (KDOQI) [6].

| Stage | eGFR | Micro- or Macroalbuminuria |
|-------|------|---------------------------|
| 1     | ≥90  | Obligate                  |
| 2     | 60–89| Obligate                  |
| 3     | 30–59| Not obligate              |
| 4     | 15–29| Not obligate              |
| 5     | <15  | Not obligate              |

eGFR = estimated glomerular filtration rate [mL/min/1.73 m²]. Chronic renal failure is defined as persistent renal impairment >3 months [6]. Stages 1 and 2 require micro- or macroalbuminuria in addition to reduced eGFR. Stages 3–5 only require reduced eGFR.

Creatinine is the most common endogenous marker used to calculate eGFR (eGFR<sub>crea</sub>). It is a break-down product from muscle tissue, and plasma levels are influenced by muscle mass, meat intake but also dehydration [1]. Low muscle mass, sarcopenia, is common in the elderly [7], but is to a higher extent associated with frailty [8,9]. Sarcopenic obesity is not uncommon in this patient group [10]. In these circumstances, BMI becomes a blunt measure of muscle mass.

Cystatin C is an alternative endogenous protein used to estimate renal function (eGFR<sub>cys</sub>). It is a protease inhibitor produced by all nucleated cells and is not affected by muscle mass [1,2], but may be affected by other factors including hypo- and hyperthyroidism (falsely decreased and falsely elevated, respectively) [1,2] and high-dose steroid therapy (falsely elevated) [1,11]. In Sweden, Cystatin C is approximately seven times more expensive to analyze compared to creatinine.

The best estimate of GFR is, however, obtained by calculating the mean of eGFR<sub>crea</sub> and eGFR<sub>cys</sub> (eGFR<sub>crea+cys</sub>), alternatively from composite equations using both markers [1,12–19]. In 2012, the Swedish Council on Health Technology Assessment (SBU) published an extensive systematic review on methods to estimate and measure renal function (1). They concluded that creatinine and cystatin C equations are equivalent in younger patients, but evidence was lacking in the elderly population. Since then, several studies on different equations have shown that eGFR<sub>crea</sub> and eGFR<sub>cys</sub> are equivalent also in the elderly [12,14–16,18,20–24]. However, a majority of the studies have been conducted on patients referred for GFR measurement, patients connected to nephrology clinics or on large study cohorts in an outpatient setting. Frail elderly people represent the majority of patients in geriatric wards [25–27]. Increasing frailty predisposes risks for inpatient care [26,28]. GFR measurement is rarely indicated in these patients. This might explain why the geriatric context is sparsely represented in the literature. After SBU’s extensive report, two studies have been conducted in geriatric clinics globally, which compare eGFR<sub>crea</sub> and eGFR<sub>cys</sub> with mGFR [20,29]. Another study has been conducted in a nursing home but did only relate eGFR<sub>crea</sub> with eGFR<sub>cys</sub> without having mGFR as reference [30]. No previous study has compared eGFR<sub>crea</sub> with eGFR<sub>cys</sub> in frail patients in a geriatric inpatient clinic.

The aim of the present study was to compare eGFR<sub>crea</sub> and eGFR<sub>cys</sub> in frail patients in a geriatric inpatient clinic. The hypothesis was that eGFR<sub>crea</sub> and eGFR<sub>cys</sub> differ significantly from each other where Cystatin C estimates lower GFR compared to creatinine.

2. Materials and Methods

2.1. Study Design and Study Population

This is a retrospective, cross-sectional study at Jakobsberg Geriatric Clinic in Stockholm, Sweden. The clinic has a capacity of 90 beds and receives referrals for acute and tertiary geriatric care from community health centers and other hospitals in Stockholm County. During February and April 2021, all patients at a designated ward were screened with both eGFR<sub>crea</sub> and eGFR<sub>cys</sub> at admission as a part of a local quality improvement work. For this study, medical records were reviewed retrospectively in order to collect eGFR<sub>crea</sub>, eGFR<sub>cys</sub> and descriptive data for each patient at admission during this period. The creatinine-based revised Lund–Malmö equation (LMR) [31] and the cystatin C-based
Caucasian-Asian-Pediatric-Adult equation (CAPA) [32] are laboratory standards in the Stockholm County and were used for calculation of eGFR.

2.1.1. Inclusion Criteria

The inclusion criteria were as follows:

- Both eGFR_{crea} and eGFR_{cys} available at admission.
- All diagnoses, sex and ages.

2.1.2. Exclusion Criteria

The exclusion criteria were as follows:

- eGFR_{cys} > 90 mL/min. When eGFR_{cys} exceeded 90 mL/min, it was only reported as ‘>90 mL/min’ in the lab results. The statistical analysis would be skewed if these values were included.

No consideration was given to thyroid disease, high-dose steroid therapy or low weight in the development of LMR and CAPA. Therefore, these were not exclusion criteria in this study. Well-controlled hypo- or hyperthyroidism is unlikely to affect plasma levels of cystatin C [33]. Similar reasoning can be seen in other studies [12,18,34]. However, we controlled for these factors to detect any differences in the results.

Thyroid disease was defined as presence of thyroid treatment at admission (ATC code H03). High-dose steroids was defined as >0.170 mg/kg/day prednisolone equivalents at admission [11]. Low weight was defined as BMI < 20 kg/m^2 (1), based on current height and weight at admission.

2.2. Data Acquisition

Descriptive data on age, sex, BMI, diagnosis (based on the 10th revision of The International Classification of Diagnosis and Related Health Problems by WHO, ICD-10), presence of thyroid disease or high-dose steroid therapy and stage of renal failure according to Kidney Disease Outcomes Quality Initiative (KDOQI) [6] were collected. However, no consideration was given to proteinuria and whether it was acute or chronic renal failure.

Laboratory Analyses

Blood samples of creatinine and cystatin C were collected at admission and were analyzed using Siemens ADVIA XPT. For creatinine, the enzymatic colorimetric method was used with Siemens ADVIA Chemistry Enzymatic Creatinine_2 reagent (traceable to the international reference material SRM967 from the National Institute for Standards and Technology). For cystatin C, the particle-enhanced immunoturbimetric method was used with reagents from Gentian (traceable to the international reference material ERM-DA471/IFCC).

2.3. Outcome Measures

The primary outcome measure was comparison of relative eGFR_{crea} and eGFR_{cys}. Similar to other studies on mixed age populations [34,35] and children [36], absolute mean difference between eGFR_{crea} and eGFR_{cys} (|ΔeGFR_{mean}|), expressed as a percentages, was used for the analysis instead of comparison with mGFR:

$$|ΔeGFR_{mean}| = \frac{|eGFR_{crea} - eGFR_{cys}|}{eGFR_{crea} + eGFR_{cys}}$$

|ΔeGFR_{mean}| ≥ 40% was considered significant, as larger discrepancy has been shown to be associated with low accuracy in eGFR_{crea} and/or eGFR_{cys} [34,35]. Proportion of |ΔeGFR_{mean}| ≥ 40% was also calculated. The secondary outcome measure was concordance between eGFR_{crea} and eGFR_{cys}, expressed in Lin’s concordance correlation coefficient (CCC). The tertiary outcome measure was proportion of consistent staging of renal failure between eGFR_{crea} and eGFR_{cys}. Subgroup analyses were performed with regard to frailty.
according to Clinical Frailty Scale (CFS) [37,38] and three pre-defined age groups: <80 years, 80–89 years and ≥90 years.

2.3.1. Lin’s Concordance Correlation

CCC is considered the most appropriate measure of concordance for methods measuring the same continuous variable [39]. Unlike other correlation measures, CCC also accounts for the vertical shift of the regression line from $y = x$ which corresponds to perfect concordance [40]. Pearson correlation coefficient ($r$) measures the correlation between different variables and is inappropriate in concordance studies [41]. Like other correlation measures, CCC yields a value between -1 (perfect negative concordance) and 1 (perfect positive concordance), where interpretation of the result depends on the clinical context. A more conservative interpretation of CCC compared to other correlation measures has been proposed: >0.99 indicates very good concordance, 0.95–0.99 good, 0.9–0.95 moderate and <0.9 unsatisfactory concordance [42].

2.3.2. Clinical Frailty Scale

While there is yet no general definition of frailty, there are several frailty scales in the field. One of the most common is CFS [43]. CFS grades habitual frailty on a nine-point scale based on nursing needs, activities of daily living (ADL), physical function and morbidity [37,38]. Habitual frailty is defined as functional status two weeks prior to the assessment [38]. In the development of the scale, patients <65 years of age and individuals with disabilities were excluded. CFS was developed to identify patients at high risk of adverse events (e.g., pressure ulcers and malnutrition) in a standardized way to enable patient-centered care [37,38]. The scale can be dichotomized, where CFS 1–4 correspond to non-frail (“robust”) and CFS 5–9 to frail [26–28]. CFS 9 means that the patient is terminally ill. In this study, frailty was graded during interdisciplinary conferences, attended by physicians, nurses, assistant nurses, occupational therapists and physiotherapists. The staff were not informed about the study’s outcome measures.

2.4. Statistical Analyses

Median and interquartile range (IQR) for continuous variables and percentages for categorical variables were used for descriptive purposes. eGFR_{crea} and eGFR_{cys} were compared using the Wilcoxon signed-rank test. Normally distributed groups were compared using ANOVA and non-normally distributed groups and ordinal data were compared using the Kruskal–Wallis test. Individual means were analyzed using one-sample t-test. Simple linear regression was used to test if CFS and age as independent variables significantly predicted $|\Delta eGFR_{mean}|$. Proportions were compared using the $\chi^2$-test or Fisher’s exact test. Data was considered normally distributed if the Shapiro–Wilk test $\geq 0.05$. $p < 0.05$ was considered statistically significant. The confidence level for confidence intervals was set to 95%. Statistical analyses were performed using jamovi (version 1.6.18.0 for Mac), except for power calculations where SPSS (version 1.0.0.1508 for Mac) was used.

Power

A power calculation was performed a priori. In a large European study on a heterogeneous age cohort ($n = 1200$, median age = 63 years, SD = 20) $|\Delta eGFR_{mean}| = 23\%$ [34]. Thirteen subjects were required in our study to detect $|\Delta eGFR_{mean}| \geq 40\%$ ($\alpha = 0.05$, power 80%).

3. Results

3.1. Descriptive Statistics

A total of 111 patients were admitted during the study period. Cystatin C was not analyzed in 13 patients. Three patients had eGFR_{cys} > 90 mL/min/1.73 m$^2$ and were excluded. In total, 95 patients fulfilled the inclusion criteria and were included in the final
Six of the subjects were not graded according to CFS and six subjects were <65 years old. Patient characteristics are presented in Table 2.

Table 2. Patient characteristics. Continuous variables are reported as median (IQR). Categorical variables are reported as percentages.

|                      | All (n = 95) | CFS 1–4 (n = 20) | CFS 5–9 (n = 63) |
|----------------------|--------------|------------------|------------------|
| **Age**              | 84 (76–89)   | 80 (74–85)       | 85 (78–90)       |
| **CFS**              | 6 (3–7)      | 3 (3–4)          | 6 (4–7)          |
| **Women**            | 56%          | 60%              | 57%              |
| **Men**              | 44%          | 40%              | 43%              |
| **BMI**              | 24.4 (21.8–28.4) | 25.0 (22.3–28.9) | 24.2 (21.7–27.8) |
| **Length of stay, days** | 6 (4–8)   | 6 (4–10)         | 7 (4–8)          |
| **Stage of renal failure** | 2 (2–3) | 2 (2–2)          | 3 (2–3)          |
| **eGFRcrea**         | 2 (2–3)      | 2 (2–2)          | 3 (2–3)          |
| **Stage of renal failure** | 3 (2–4) | 2 (2–3)          | 3 (3–4)          |
| **eGFRcys**          |              |                  |                  |
| **Treatment for thyroid disease** | 17%       | 10%              | 19%              |
| **High-dose steroid therapy** | 8%       | 10%              | 10%              |

Abbreviations: BMI = body mass index [kg/m²]; CFS = Clinical Frailty Scale; eGFRcrea = eGFR with creatinine; eGFRcys = eGFR with cystatin C. Patients assessed according to CFS were fewer than the total number of patients as six patients were <65 years old and another six patients were not assessed according to CFS. CFS 1–4 corresponds to non-frail (“robust”) patients and CFS 5–9 to frail patients. Staging of renal failure is according to KDOQI (no consideration was given to proteinuria and whether it was acute or chronic renal failure). High-dose steroid therapy was defined as >0.170 mg/kg/day prednisolone equivalents at admission.

A total of 76% of patients ≥ 65 years old were graded as frail, 16% had a BMI of <20 kg/m² and 30% had renal impairment corresponding to stage 4 or 5. Frail patients were older than non-frail patients (p = 0.023). Frail patients were at a later stage of renal failure as estimated with both creatinine (p = 0.014) and cystatin C (p < 0.01). No statistically significant difference between frail and non-frail could be detected with regard to BMI (p = 0.49), proportion of thyroid treatment (p = 0.35), high-dose steroid therapy (p = 0.95) and length of stay (p = 0.93). Only one patient was terminally ill, i.e., CFS = 9.

The distribution of diagnoses is shown in Table 3. The most common were musculoskeletal, cardiological as well as urogenital and nephrological diagnoses. Osteoporosis-related fracture (including hip fracture) was the most common diagnosis (18%). Among cardiological diagnoses, heart failure was the most common (15%). In the urogenital and nephrological group, the most common diagnosis was urinary tract infection (8%). The distribution of diagnoses did not differ statistically significant between frail and non-frail patients (p = 0.19).

Table 3. Distribution of diagnoses in the study population based on ICD-10 (n = 95).

| Diagnosis                                | Percentage |
|------------------------------------------|------------|
| Musculoskeletal (including fractures)    | 26%        |
| Cardiological                            | 17%        |
| Urogenital and nephrological             | 15%        |
| Lung diseases                            | 8%         |
| Gl-related                               | 6%         |
| Neurological                             | 5%         |
| Neoplasms                                | 4%         |
| Mental and behavioral disorders          | 4%         |
| Diabetes                                 | 2%         |
| Infectious diseases                      | 2%         |
| Other                                    | 10%        |
3.2. Outcome Measures
3.2.1. Primary Outcome Measure

Cystatin C estimated lower GFR than creatinine across the entire study population, as well as in all subgroups (Figures 1 and 2).

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Box-and-Whisker plot showing median and range of eGFR estimated with the creatinine and cystatin C in geriatric and frail patients. The table below shows median and interquartile range (IQR). p-values were calculated with the Wilcoxon signed-rank test.

|                | All (n=95) | CFS 1-4 (n=20) | CFS 5-9 (n=63) | <80 years (n=37) | 80-89 years (n=36) | ≥90 years (n=22) |
|----------------|------------|----------------|----------------|------------------|-------------------|------------------|
| eGFR<sub>crea</sub> | 64 (42-78) | 71 (64-77)     | 55 (36-74)     | 78 (67-89)       | 55 (39-69)        | 46 (21-62)       |
| eGFR<sub>cys</sub>  | 42 (28-63) | 62 (47-64)     | 34 (22-53)     | 54 (36-67)       | 38 (26-55)        | 32 (24-49)       |
| p               | <0.01      | <0.01          | <0.01          | <0.01            | <0.01             | 0.045            |

![Figure 2](https://example.com/figure2.png)

**Figure 2.** Paired estimates and CCC for eGFR<sub>crea</sub> and eGFR<sub>cys</sub> in geriatric patients. The dashed line corresponds to the regression line for eGFR<sub>crea</sub> and eGFR<sub>cys</sub>. The solid line corresponds to perfect concordance (i.e., eGFR<sub>crea</sub> = eGFR<sub>cys</sub>). eGFR<sub>crea</sub> > eGFR<sub>cys</sub> when a paired estimate is above the solid line, and vice versa.

\[|\Delta\text{eGFR}_{\text{mean}}| \text{ was greater in frail compared to non-frail patients (} p < 0.01\text{)} (Table 4).\]

Controlling for thyroid disease, high-dose steroid therapy and BMI < 20 kg/m\(^2\) did not affect the result significantly (\(p = 0.011\)). No statistically significant difference was detected between the age groups (\(p = 0.97\)). \(|\Delta\text{eGFR}_{\text{mean}}| \text{ exceeded 40% only in frail patients but was not statistically significant (} p = 0.31\text{). The proportion of } |\Delta\text{eGFR}_{\text{mean}}| \geq 40\% \text{ was greater in frail compared to non-frail patients (} p < 0.01\text{). This was not observed between the age groups (} p = 0.39\).\]
Table 4. Outcome measures for comparison of creatinine and cystatin C to estimate renal function in geriatric and frail patients [95% CI].

|               | All (n = 95) | CFS 1–4 (n = 20) | CFS 5–9 (n = 63) | <80 Years (n = 37) | 80-89 Years (n = 36) | ≥90 Years (n = 22) |
|---------------|--------------|------------------|------------------|-------------------|---------------------|------------------|
| ∆eGFRmean    | 37% [32, 42] | 23% [16, 31]     | 42% [35, 48]     | 38% [29, 46]      | 37% [29, 45]        | 34% [25, 44]     |
| Proportion of |              |                  |                  |                   |                     |                  |
| ∆eGFRmean ≥ 40% | 41% [32, 51] | 18% [5, 36]      | 52% [40, 64]     | 32% [20, 49]      | 47% [32, 63]        | 45% [27, 65]     |
| CCC          |              |                  |                  |                   |                     |                  |
|              | 0.66 [0.55, 0.74] | 0.65 [0.08, 0.72] | 0.61 [0.47, 0.72] | 0.49 [0.31, 0.64] | 0.64 [0.46, 0.77]   | 0.80 [0.59, 0.91] |
| Consistent staging of renal failure |              |                  |                  |                   |                     |                  |
|              | 44% [35, 54] | 65% [43, 82]     | 38% [27, 50]     | 41% [26, 57]      | 47% [32, 63]        | 46% [27, 65]     |

Abbreviations: ∆eGFRmean = absolute mean difference between eGFRcrea and eGFRcys (|eGFRcrea – eGFRcys|/(eGFRcrea + eGFRcys)/2); CCC = Lin’s concordance correlation coefficient.

Simple linear regression was used to test if CFS and age as independent variables significantly predicted ∆eGFRmean (Table 5). Age was a continuous variable in the regression (not stratified into different age groups). It was found that CFS significantly predicted ∆eGFRmean, i.e., ∆eGFRmean increased by 3.1–9.9 percentage points (95% CI) for each level in CFS (p < 0.01). Notably, age did not significantly predict ∆eGFRmean (p = 0.55).

Table 5. Simple linear regression for CFS and age as independent variables for ∆eGFRmean [95% CI].

|               | CFS (n = 83) | Age (n = 95) |
|---------------|--------------|--------------|
| β-coefficient | 0.065 **     | −0.002       |
| r^2           | 0.015        | 0.004        |
| Intercept     | −0.19        | 0.50 *       |

** p < 0.01; * p < 0.05; β-coefficient = slope.

3.2.2. Secondary Outcome Measure

Figure 2 shows paired estimates of eGFRcrea and eGFRcys with CCC as a concordance measure. The dashed line corresponds to the regression line for eGFRcrea and eGFRcys, and the solid line corresponds to perfect concordance (i.e., eGFRcrea = eGFRcys). CCC was 0.66 for the entire study population, 95% CI [0.55, 0.74] and did not reach 0.95 (i.e., cut-off value for good concordance) in any subgroup (Table 4).

3.2.3. Tertiary Outcome Measure

The consistency regarding staging of renal failure with eGFRcrea and GFRcys, respectively, was 44% for the entire study population (Table 4). The consistency was lower in frail compared to non-frail (p = 0.035) patients. A statistically significant difference could not be detected between the different age groups (p = 0.84).

4. Discussion

The eGFRcys estimated lower GFR than eGFRcrea across the entire study population as well as in all subgroups. This is in line with several other studies on elderly patients [12,14–16,18,20,23,24,29,44–46] published after SBU’s systematic review from 2012 [1]. A majority of these studies have also had mGFR as reference [12,14–16,18,20,23,24,29]. However, no study has been able to demonstrate which estimate is preferable over the other. A majority still conclude that eGFRcrea + cys is favorable also in the elderly [12,14–16,18]. One Swedish and one Chinese study have been conducted comparing eGFR with mGFR in
patients admitted to geriatric clinics \([20,29]\). In the Chinese study \((n = 110)\), cystatin C generally estimated lower GFR than mGFR \([29]\). Both equations based on creatinine (CKD-EPI) and cystatin C (Tan, Macluska) had acceptable accuracy at \(\text{mGFR} > 60 \text{ mL/min/1.73 m}^2\). However, only cystatin C-based equations (Macluska, Ma) had an acceptable accuracy at \(\text{mGFR} < 60 \text{ mL/min/1.73 m}^2\). In the Swedish study \((n = 108)\), all equations (Cockroft–Gault; MDRD4; CKD-EPI; CAPA; BIS2) had insufficient accuracy except Cockroft–Gault \([20]\). Interestingly, in contradiction to this, Cockroft–Gault is generally not recommended in clinical practice due to its lack of accuracy \([1]\).

In this study, discrepancy between eGFR\textsubscript{crea} and eGFR\textsubscript{cys} increased with increasing frailty. This could not be observed for increasing age. This indicates that increasing frailty rather than aging reduces accuracy of eGFR. However, the results must be interpreted with caution as it is a cross-sectional study with a relatively small sample size and conclusions about causality can therefore not be drawn \([41]\).

The proportion of \(\mid \Delta \text{eGFR}_{\text{mean}} \mid \geq 40\%\) was 41\% for the entire study population, 95\% CI [32\%, 51\%], and 52\% for frail patients, 95\% CI [40\%, 64\%]. This complicates routine calculation of eGFR\textsubscript{crea+cys} in this patient group as it is not valid when \(\mid \Delta \text{eGFR}_{\text{mean}} \mid\) exceeds 40\% \([34]\). In contrast, \(\mid \Delta \text{eGFR}_{\text{mean}} \mid\) was 18\%, 95\% CI [16\%, 21\%], in a large European study on a heterogeneous age cohort \((n = 1200, \text{median age} = 63 \text{ years})\) \([34]\).

CCC did not reach 0.95 for all subjects or in any subgroup, which has been suggested as minimum value for good concordance \([42]\). However, this is the first study with CCC in this context, why significance assessment and comparison with other studies are not possible. There have been previous concordance studies on eGFR\textsubscript{crea} and eGFR\textsubscript{cys} in the elderly. They have, however, used intraclass correlation for the analyses, which is inferior to CCC for continuous variables \([39,40,42]\). We welcome more studies using CCC.

The staging of renal failure with eGFR\textsubscript{crea} and eGFR\textsubscript{cys}, respectively, was consistent in almost 50\% of the cases. This is in line with another study in elderly patients \((n = 60)\), where mean consistency was 40–62\% \([47]\). In our study, consistency was even lower in frail patients. However, there is an inherent uncertainty in equations for eGFR. According to international practice, an equation’s performance is assessed by bias and accuracy \([1]\). Bias refers to the mean or median difference between eGFR and mGFR, where >10\% often is considered significant \([1]\). Accuracy refers to the proportion of estimates within a predetermined margin of error from mGFR \([1]\). A generally accepted proportion and margin of error is 80\% and ±30\%, respectively \([1]\). In summary, an equation is accepted even if there is a relatively large spread in up to 20\% of the estimates, provided that the mean or median difference from mGFR is less than 10\%. This has implications on drug dosing. In a Danish study \((n = 338)\) of acutely ill elderly patients, 9.9–19.1\% would have received a higher dose than recommended of at least one drug, depending on which equation that was used (CKD-EPI; BIS; Cockroft–Gault) \([13]\). Studies on adverse drug reactions or treatment failure in relation to usage of different equations have, to our knowledge, not been conducted. An additional difficulty with regard to drug dosing is that Cockroft–Gault is still recommended in clinical trials \([48]\).

Several explanations for why cystatin C consistently estimate lower GFR in the elderly compared to creatinine have been presented. Muscle mass decreases with age, which masks deteriorated creatinine have been presented. Muscle mass decreases with age, which masks deteriorated creatinine levels \([49–52]\). A number of cross-sectional studies have shown correlation between sarcopenia and increasing creatinine-cystatin C ratio, i.e., the sarcopenia index \([13,49,53–55]\). No study has investigated the relationship between sarcopenia and accuracy of eGFR. Another theory is the shrunken pore syndrome, which causes shrinkage of pores in glomeruli \((61)\). Large molecules, e.g., cystatin C (13 kDa), are then eliminated to a lesser extent, in contrast to small molecules, e.g., creatinine (0.12 kDa), which continue to be filtered freely \([56]\). This might explain why plasma levels of creatinine are not reduced until half of the nephrons are affected \([57,58]\). Consequently, toxins accumulate and cause a negative spiral with increased atherosclerosis and nephrosclerosis \([31]\). Several studies have been made to identify additional non-GFR determinants that affects creatinine and cystatin C levels, e.g., inflammation,
diabetes, cancer and smoking. However, the results are contradictory and come mostly from cross-sectional studies [58,59]. It has been suggested that the improved accuracy in eGFR\textsubscript{crea+cys} is due to each marker’s compensation for the other’s disadvantages [14]. In this study, we chose to control for the main non-GFR determinants suggested by SBU, i.e., thyroid disease, high-dose steroid therapy and underweight [1].

Strengths and Limitations
This is the first study to investigate the association between uncertainty in renal function estimation and CFS. A similar study (n = 55) has been done on psychiatric patients, but no correlation was detected between frailty and difference between eGFR\textsubscript{crea} and eGFR\textsubscript{cys} [44]. That study also used a different frailty scale (Rockwood Frailty Index) and had methodological differences compared ours. A strength of our study is that CFS was assessed during a multidisciplinary round. Inter-rater reliability for CFS is good in non-acute settings [25,37], in contrast to initial estimation in the emergency department where concordance has shown to be lacking [43]. Furthermore, the assessors of CFS were not aware of the outcome measures in this study, which reduces risk of bias. This is the first study using both LMR and CAPA in a geriatric context. CCC is rarely used in medical research despite its advantage when evaluating continuous variables and has never been used to evaluate consistency between different eGFR equations.

This study has several limitations. We were not able to analyze mGFR due to time-constraints. Instead, |\Delta eGFR\textsubscript{mean}| was used as a surrogate measure of accuracy. |\Delta eGFR\textsubscript{mean}| has indeed been evaluated in previous studies [34,35], but cannot be considered as an accepted measure of accuracy. The study was underpowered to detect |\Delta eGFR\textsubscript{mean}| ≥ 40% in frail patients. Post hoc power was 28% to detect |\Delta eGFR\textsubscript{mean}| ≥ 40% for all patients and 10% for frail patients. A total of 1924 patients would have been required to reach statistical power of 80% in the frail group, which is significantly more than predicted. This may be explained partly by a greater spread in the estimates (SD = 25% for all patients; SD = 27% for frail; SD = 18% for non-frail) compared to the study which served as basis for the power calculation a priori [12]. Furthermore, this is a single-center cross-sectional study and it is therefore not possible to draw conclusions about causality [41]. Prospective studies are necessary to answer this question.

This study was conducted in an acute geriatric setting. Acute illness is more likely to contribute to bias and is for that reason often used as an exclusion criterion in similar studies [15,16,19,22–24,29,49,50]. On the other hand, acute illness is a clinical reality and including such patients may give a better picture of daily practice. Finally, this study cannot conclude whether eGFR\textsubscript{crea} or eGFR\textsubscript{cys} is preferable in this patient group since they were not compared to mGFR. Instead, the results from this study may provide a valuable background for the design and hypothesis in a future, prospective study where the estimates are compared with mGFR.

5. Conclusions
The results suggest that eGFR\textsubscript{crea} and eGFR\textsubscript{cys} differ significantly in geriatric and frail patients, where cystatin C estimates lower GFR compared to creatinine. Furthermore, this study suggests that frailty according to CFS may have greater impact than age on the accuracy of GFR. The study cannot determine whether one of the GFR estimates is preferable to the other in these individuals. To answer this, studies comparing eGFR with mGFR are needed. Calculating eGFR\textsubscript{crea+cys} has been shown to increase accuracy in other patients but may be difficult to introduce as routine practice in geriatric care, as the difference between the estimates was too large in almost 50% of the cases.

Author Contributions: Conceptualization, E.D. and L.B.-B.; methodology, E.D.; software, E.D.; validation, E.D. and L.B.-B.; formal analysis, E.D.; investigation, E.D.; resources, E.D. and L.B.-B.; data curation, E.D. and L.B.-B.; writing—original draft preparation, E.D.; writing—review and editing, E.D. and L.B.-B.; visualization, E.D.; supervision, L.B.-B.; project administration, E.D. and L.B.-B.; funding acquisition, L.B.-B. All authors have read and agreed to the published version of the manuscript.
Funding: E.D. had no external funding. L.B.-B. has research time funded by the Swedish Cancer Society and Stockholm County Council. The funding body had no influence on the content of this re-view, the writing of the manuscript, or in the decision to publish the results.

Institutional Review Board Statement: The study was assessed and approved by the Swedish Ethical Review Authority (2022-00556-01 11 April 2022).

Informed Consent Statement: This was a retrospective study and informed consent was obtained retrospectively, in accordance with the decision from the Swedish Ethical Review Authority.

Data Availability Statement: Raw data is available from the corresponding author on request.

Acknowledgments: The authors want to thank Evy Wiklund for help with extracting data from the medical records, to Eli Zahou and Kristina Siversen at Unilabs for guidance in clinical chemistry and to Ulf Nyman for sharing data from his and colleagues’ studies. The authors also want to express their sincere gratitude to the head of the department, Håkan Erlandsson, for approval and support throughout the project.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Skattnings av njurfunktion: En Systematisk Litteraturöversikt [Methods to Estimate and Measure Renal Function (Glomerular Filtration Rate): A Systematic Review]. Swedish. Available online: http://www.sbu.se/sv/Publicerat/Gul/Skattnings-av-njurfunktion (accessed on 3 June 2022).
2. Fehrman-Ekholm, I.; Seeberger, A.; Björk, J.; Sterner, G. Serum cystatin C: A useful marker of kidney function in very old people. Scand. J. Clin. Lab. Invest. 2009, 69, 606–615. [CrossRef]
3. Corsonello, A.; Pedone, C.; Corica, F.; Mussi, C.; Carbonin, P.; Antonelli Incalzi, R. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch. Intern. Med. 2005, 165, 790–795. [CrossRef]
4. Läkemedelsorsakad Sjuklighet Hos Äldre [Adverse Drug Reactions in the Elderly]. Swedish. Available online: https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/ovrigt/2014-12-13.pdf (accessed on 3 June 2022).
5. Hoogendijk, E.O.; Afilalo, J.; Ensrud, K.E.; Kowal, P.; Onder, G.; Fried, L.P. Frailty: Implications for clinical practice and public health. Lancet 2019, 394, 1365–1375. [CrossRef]
6. Levey, A.S.; Coresh, J.; Balk, E.; Kausz, A.T.; Levin, A.; Steffes, M.W.; Hogg, R.J.; Perrone, R.D.; Lau, J.; Eknoyan, G. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Amn. Intern. Med. 2003, 139, 137–147. [CrossRef]
7. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 2019, 48, 601. [CrossRef]
8. Smithard, D.; Hansjee, D.; Henry, D.; Mitchell, L.; Sabaharwal, A.; Salkeld, J.; Yeung, E.; Younus, O.; Swaine, I. Inter-Relationships between Frailty, Sarcopenia, Undernutrition and Dysphagia in Older People Who Are Admitted to Acute Frailty and Medical Wards: Is There an Older Adult Quartet? Geriatrics 2020, 5, 41. [CrossRef]
9. Kamijo, Y.; Kanda, E.; Ishibashi, Y.; Yoshida, M. Sarcopenia and Frailty in PD: Impact on Mortality, Malnutrition, and Inflammation. Perit. Dial. Int. 2018, 38, 447–454. [CrossRef]
10. Zamboni, M.; Mazzali, G.; Fantin, F.; Rossi, A.; Di Francesco, V. Sarcopenic obesity: A new category of obesity in the elderly. Nutr. Metab. Cardiovasc. Dis. 2008, 18, 388–395. [CrossRef]
11. Tsushita, H.; Tanaka, R.; Suzuki, Y.; Sato, Y.; Itoh, H. Effects of dose and type of corticosteroids on the divergence between estimated glomerular filtration rates derived from cystatin C and creatinine. J. Clin. Pharm. Ther. 2020, 45, 1390–1397. [CrossRef]
12. Björk, J.; Bäck, S.E.; Ebert, N.; Evans, M.; Grubb, A.; Hansson, M.; Jones, I.; Lamb, E.J.; Martus, P.; Schaeffner, E.; et al. GFR estimation based on standardized creatinine and cystatin C: A European multicenter analysis in older adults. Clin. Chem. Lab. Med. 2018, 56, 422–435. [CrossRef]
13. Iversen, E.; Bodilsen, A.C.; Klausen, H.H.; Tredal, C.; Andersen, O.; Houllind, M.B.; Petersen, J. Kidney function estimates using cystatin C versus creatinine: Impact on medication prescribing in acutely hospitalized elderly patients. Basic Clin. Pharmacol. Toxicol. 2019, 124, 466–478. [CrossRef] [PubMed]
14. Fan, L.; Levey, A.S.; Gudmunsdottir, V.; Eiriksdottir, G.; Andresdottir, M.B.; Gudmundsdottir, H.; Indridason, O.S.; Palsson, R.; Mitchell, G.; Inker, L.A. Comparing GFR Estimating Equations Using Cystatin C and Creatinine in Elderly Individuals. J. Am. Soc. Nephrol. 2015, 26, 1982–1989. [PubMed]
15. Ye, X.; Wei, L.; Pei, X.; Zhu, B.; Wu, J.; Zhao, W. Application of creatinine- and/or cystatin C-based glomerular filtration rate estimation equations in elderly Chinese. Clin. Intero. Aging 2014, 9, 1539–1549. [CrossRef]
16. Lopes, M.B.; Araújo, L.Q.; Passos, M.T.; Nishida, S.K.; Kirsztajn, G.M.; Cendoroglo, M.S.; Sesso, R.C. Estimation of glomerular filtration rate from serum creatinine and cystatin C in octogenarians and nonagenarians. BMC Nephrol. 2013, 14, 265. [CrossRef] [PubMed]
17. Liu, X.; Ma, H.; Huang, H.; Wang, C.; Tang, H.; Li, M.; Wang, Y.; Lou, T. Is the Chronic Kidney Disease Epidemiology Collaboration creatinine-cystatin C equation useful for glomerular filtration rate estimation in the elderly? *Clin. Interv. Aging* 2013, 8, 1387–1391. [CrossRef]

18. Björk, J.; Grubb, A.; Gudnason, V.; Indridason, O.S.; Levey, A.S.; Palsson, R.; Nyman, U. Comparison of glomerular filtration rate estimating equations derived from creatinine and cystatin C: Validation in the Age, Gene/Environment Susceptibility-Reykjavik elderly cohort. *Nephrol. Dial. Transplant.* 2018, 33, 1380–1388. [CrossRef]

19. Huang, Q.; Sun, X.; Chen, Y.; Zhang, M.; Tang, L.; Liu, S.; Wei, R.; Wang, S.; Zhou, J.; Cao, X.; et al. A Study of the Applicability of GFR Evaluation Equations for an Elderly Chinese Population. *J. Nutr. Health Aging* 2015, 19, 693–701. [CrossRef]

20. Helldén, I.; Bergman, U.; Odar-Cederlöf, I. The importance of correct estimation of renal function for drug treatment in hospitalized elderly patients, especially women: A prospective observational study. *Clin. Nephrol.* 2019, 91, 254–264. [CrossRef]

21. Bevc, S.; Hojs, N.; Hojs, R.; Ekart, R.; Gorenjak, M.; Puklavec, L. Estimation of Glomerular Filtration Rate in Elderly Chronic Kidney Disease Patients: Comparison of Three Novel Sophisticated Equations and Simple Cystatin C Equation. *Ther. Apher. Dial.* 2017, 21, 126–132. [CrossRef]

22. Jalaloumuhali, M.; Elgel, S.M.A.; Tan, M.P.; Lim, S.K.; Ng, K.P. Estimating Renal Function in the Elderly Malaysians Patients Attending Medical Outpatient Clinic: A Comparison between Creatinine Based and Cystatin-C Based Equations. *Int. J. Nephrol.* 2018, 2018, 3081518. [CrossRef]

23. Kilbride, H.S.; Stevens, P.E.; Eaglestone, G.; Knight, S.; Carter, J.L.; Delaney, M.P.; Farmer, C.K.; Irving, J.; O’Riordan, S.E.; Dalton, R.N.; et al. Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly. *Am. J. Kidney Dis.* 2013, 61, 57–66. [CrossRef][PubMed]

24. Zhu, Y.; Ye, X.; Zhu, B.; Pei, X.; Wei, L.; Wu, J.; Zhao, W. Comparisons between the 2012 new CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equations and other four approved equations. *PLoS ONE* 2014, 9, e84688. [CrossRef][PubMed]

25. Chua, X.Y.; Toh, S.; Wei, K.; Teo, N.; Tang, T.; Wee, S.L. Evaluation of clinical frailty screening in geriatric acute care. *J. Eval. Clin. Pract.* 2020, 26, 35–41. [CrossRef]

26. Nguyen, T.V.; Ly, T.T.; Nguyen, T.N. A Pilot Study of the Clinical Frailty Scale to Predict Frailty Transition and Readmission in Older Patients in Vietnam. *Int. J. Environ. Res. Public Health* 2020, 17, 1582. [CrossRef]

27. Chong, E.; Ho, E.; Baldevarona-Llego, J.; Chan, M.; Wu, L.; Tay, L.; Ding, Y.Y.; Lim, W.S. Frailty in Hospitalized Older Adults: Comparing Different Frailty Measures in Predicting Short- and Long-Term Patient Outcomes. *J. Am. Med. Dir. Assoc.* 2018, 19, 450–457.e3. [CrossRef][PubMed]

28. Kahlon, S.; Pederson, J.; Majumdar, S.R.; Belga, S.; Lau, D.; Fradette, M.; Boyko, D.; Bakal, J.A.; Johnston, C.; Padwal, R.S.; et al. Association between frailty and 30-day outcomes after discharge from hospital. *CMAJ* 2015, 187, 799–804. [CrossRef]

29. Pei, X.; Liu, Q.; He, J.; Bao, L.; Yan, C.; Wu, J.; Zhao, W. Are cystatin C-based equations superior to creatinine-based equations for estimating GFR in Chinese elderly population? *Int. Urol. Nephrol.* 2012, 44, 1877–1884. [CrossRef][PubMed]

30. Bolmsjö, B.B.; Mölstad, S.; Gallagher, M.; Chalmers, J.; Östgren, C.J.; Midlöv, P. Risk factors and consequences of decreased kidney function in nursing home residents: A longitudinal study. *Geriatr. Gerontol. Int.* 2017, 17, 791–797. [CrossRef]

31. Björk, J.; Grubb, A.; Sterner, G.; Nyman, U. Revised equations for estimating glomerular filtration rate based on the Lund-Malmö Study cohort. *Scand. J. Clin. Lab. Invest.* 2011, 71, 232–239. [CrossRef]

32. Grubb, A.; Horio, M.; Hansson, L.O.; Björk, J.; Nyman, U.; Flodin, M.; Larsson, A.; Bökenkamp, A.; Yasuda, Y.; Blufpand, H.; et al. Generation of a new cystatin C-based estimating equation for glomerular filtration rate by use of 7 assays standardized to the international calibrator. *Clin. Chem.* 2014, 60, 974–986. [CrossRef]

33. Suzuki, Y.; Matsushita, K.; Seimiya, M.; Yoshida, T.; Sawabe, Y.; Ogawa, M.; Nomura, F. Paradoxical effects of thyroid function on glomerular filtration rate estimated from serum creatinine or standardized cystatin C in patients with Japanese Graves’ disease. *Clin. Chim. Acta* 2015, 451, 316–322. [CrossRef][PubMed]

34. Björk, J.; Grubb, A.; Larsson, A.; Hansson, L.O.; Flodin, M.; Sterner, G.; Lindström, V.; Nyman, U. Accuracy of GFR estimating equations combining standardized cystatin C and creatinine assays: A cross-sectional study in Sweden. *Clin. Chem. Lab. Med.* 2015, 53, 403–414. [CrossRef][PubMed]

35. Grubb, A.; Nyman, U.; Björk, J. Improved estimation of glomerular filtration rate (GFR) by comparison of eGFRcystatin C and eGFRcreatinine. *Scand. J. Clin. Lab. Investig.* 2012, 72, 73–77. [CrossRef]

36. Den Bakker, E.; Musters, J.; Hubeek, I.; van Wijk, J.A.E.; Gemke, R.; Bökenkamp, A. Concordance between creatinine- and cystatin C-based eGFR in clinical practice. *Scand. J. Clin. Lab. Investig.* 2021, 81, 142–146. [CrossRef][PubMed]

37. Rockwood, K.; Song, X.; MacKnight, C.; Bergman, H.; Hogan, D.B.; McDowell, I.; Mitnitski, A. A global clinical measure of fitness and frailty in elderly people. *CMAJ* 2005, 173, 489–495. [CrossRef]

38. Rockwood, K.; Theou, O. Using the Clinical Frailty Scale in Allocating Scarce Health Care Resources. *Can. Geriatr. J.* 2020, 23, 210–215. [CrossRef]

39. Lin, H.-M.; Williamson, J. A Simple Approach for Sample Size Calculation for Comparing Two Concordance Correlation Coefficients Estimated on the Same Subjects. *J. Biopharm. Stat.* 2014, 25, 1145–1160. [CrossRef]

40. Lin, L.I. A concordance correlation coefficient to evaluate reproducibility. *Biometrics* 1989, 45, 255–268. [CrossRef][PubMed]

41. Portney, L.G. *Foundations of Clinical Research: Applications to Evidence-Based Practice*, 4th ed.; F.A. Davis: Philadelphia, PA, USA, 2020.
42. McBride, G. A proposal for strength-of-agreement criteria for Lin’s concordance correlation coefficient. In NIWA Client Report: HAM2005-062; National Institute of Water & Atmospheric Research: Hamilton, New Zealand, 2005; Volume 62.

43. Shrier, W.; Dewar, C.; Parrella, P.; Hunt, D.; Hodgson, L.E. Agreement and predictive value of the Rockwood Clinical Frailty Scale at emergency department triage. Emerg. Med. J. 2020, 38, 868–873. [CrossRef]

44. Jacobs, A.; Benraad, C.; Wetzelis, J.; Rikkert, M.O.; Kramers, C. Clinical Relevance of Differences in Glomerular Filtration Rate Estimations in Frail Older People by Creatinine- vs. Cystatin C-Based Formulas. Drugs Aging 2017, 34, 445–452. [CrossRef]

45. Yamaguchi, Y.; Itabashi, M.; Yumura, W.; Takei, T. Geriatric assessment of estimated glomerular filtration rate: A cross-sectional study. Clin. Exp. Nephrol. 2020, 24, 216–224. [CrossRef] [PubMed]

46. Husain, S.A.; Willey, J.Z.; Park Moon, Y.; Elkind, M.S.V.; Sacco, R.L.; Wolf, M.; Cheung, K.; Wright, C.B.; Mohan, S. Creatinine- versus cystatin C-based renal function assessment in the Northern Manhattan Study. PLoS ONE 2018, 13, e0206839. [CrossRef]

47. Ramel, A.; Jonsson, P.V.; Bjornsson, S.; Thorsdottir, I. Differences in the glomerular filtration rate calculated by two creatinine-based and three cystatin-C-based formulae in hospitalized elderly patients. Nephron Clin. Pract. 2008, 108, c16–c22. [CrossRef] [PubMed]

48. Pharmacokinetics in Patients with Impaired Renal Function-Study Design, Data Analysis, and Impact on Dosing and Labeling. Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-renal-function-study-design-data-analysis-and-impact-dosing-and (accessed on 3 June 2022).

49. Kawakami, M.; Hirata, S.; Mizuta, M.; Hidaka, D.; Sano, H.; Isobe, K.; Nakatani, S.; Narita, Y. Modified serum creatinine-derived equations with muscle mass-adjusted estimation of renal function and serum cystatin C-derived estimated glomerular filtration rate in elderly individuals. Int. J. Clin. Pharmacol. Ther. 2019, 57, 229–239. [CrossRef] [PubMed]

50. Ichihara, K.; Saito, K.; Itoh, Y. Sources of variation and reference intervals for serum cystatin C in a healthy Japanese adult population. Clin. Chem. Lab. Med. 2007, 45, 1232–1236. [CrossRef] [PubMed]

51. Erlandsen, E.J.; Randers, E.; Kristensen, J.H. Reference intervals for serum cystatin C and serum creatinine in adults. Clin. Chem. Lab. Med. 1998, 36, 393–397. [CrossRef]

52. Finney, H.; Newman, D.J.; Price, C.P. Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann. Clin. Biochem. 2000, 37 Pt 1, 49–59. [CrossRef] [PubMed]

53. Barreto, E.F.; Poyant, J.O.; Coville, H.H.; Dierkhising, R.A.; Kennedy, C.C.; Gajic, O.; Nystrom, E.M.; Takahashi, N.; Moynagh, M.R.; Kashani, K.B. Validation of the sarcopenia index to assess muscle mass in the critically ill: A novel application of kidney function markers. Clin. Nutr. 2019, 38, 1362–1367. [CrossRef]

54. Kashani, K.B.; Frazeè, E.N.; Kukrálöva, L.; Sarvottam, K.; Heras乙烯, V.; Young, P.M.; Kashyap, R.; Lieske, J.C. Evaluating Muscle Mass by Using Markers of Kidney Function: Development of the Sarcopenia Index. Crit. Care Med. 2017, 45, e23–e29. [CrossRef]

55. Kusunoki, H.; Tsuji, S.; Kusukawa, T.; Wada, Y.; Tamaki, K.; Nagai, K.; Itoh, M.; Sano, K.; Amano, M.; Maeda, H.; et al. Relationships between cystatin C- and creatinine-based eGFR in Japanese rural community-dwelling older adults with sarcopenia. Clin. Exp. Nephrol. 2021, 25, 231–239. [CrossRef] [PubMed]

56. Grubb, A.; Lindström, V.; Jonsson, M.; Bäck, S.E.; Åhlund, T.; Rippe, B.; Christenson, A. Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: ‘Shrunken pore syndrome’. Scand. J. Clin. Lab. Invest. 2015, 75, 333–340. [CrossRef]

57. Sharma, A.; Mucino, M.J.; Ronco, C. Renal functional reserve and renal recovery after acute kidney injury. Nephron Clin. Pract. 2014, 127, 94–100. [CrossRef] [PubMed]

58. Grubb, A.; Björk, J.; Nyman, U.; Pollak, J.; Bengzon, J.; Ostner, G.; Lindström, V. Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation. Scand. J. Clin. Lab. Invest. 2011, 71, 145–149. [CrossRef] [PubMed]

59. Legrand, H.; Werner, K.; Christenson, A.; Pihlsgård, M.; Elmståhl, S. Prevalence and determinants of differences in cystatin C and creatinine-based estimated glomerular filtration rate in community-dwelling older adults: A cross-sectional study. BMC Nephrol. 2017, 18, 350. [CrossRef] [PubMed]